NervGen Pharma Corp. NGENF
3.95 USD 0.00 (+0.00%)
Mar 11, 2026, 9:30 AM EDT
- YTD
- -29.46%
- 1 year
- +97.50%
Altman Z-Score
-3.20 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
P/E -8.7×
P/S 0.0×
P/B 81.9×
P/FCF -12.5×
EV/EBITDA -7.8×
EV/Sales 0.0×
FCF Yield -8.0%
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE -931.7%
ROIC -929.5%
ROA -123.2%
Revenue 0.0%
Operating Income -40.3%
EPS (diluted) 5.3%
Free Cash Flow -47.3%
Current Ratio 1.1×
Quick Ratio 1.1×
Debt / Equity 0.0×
Net Debt / EBITDA 0.7×
Interest Coverage 0.0×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2024-12-31